The Antibiotic Resistance Crisis: 10M Deaths Per Year by 2050 Without New Drugs

Antibiotic-resistant infections could cause 10 million deaths annually by 2050, surpassing cancer. The pipeline for new antibiotics has nearly dried up because pharmaceutical companies find them unprofitable (short treatment courses, resistance develops quickly).

The Problem

• 1.27M deaths already from antibiotic resistance (2019)
• Last truly novel antibiotic class: 1980s
• Pharma R&D: antibiotics return $1.6B vs cancer drugs $10B+
• Overuse in agriculture and human medicine accelerates resistance

Solutions

• Government push incentives (CARB-X, GARDP)
• Phage therapy (using viruses to kill bacteria)
• AI drug discovery accelerating antibiotic development
• Antimicrobial stewardship programs

Analysis

Antibiotic resistance is a slow-moving pandemic that receives far less attention than it deserves. The market failure is clear: antibiotics are socially valuable but privately unprofitable. Governments are beginning to intervene with pull incentives (guaranteed purchase agreements) and push incentives (research funding). AI drug discovery could help by reducing the $1B+ cost of developing a new antibiotic. Without intervention, routine surgeries, childbirth, and minor infections could become life-threatening again.